For using their combined expertise in virology and in multisubunit protein production to engineer virus-like particles (VLPs), which will allow for rapid testing of the neutralization capacity of recovered patient sera (in collaboration with the Blish lab) or designed antibodies targeting the S protein (in collaboration with the Wells lab).
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AKnown Financial Commitments (USD)
$0Funder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Judith FrydmanResearch Location
United States of AmericaLead Research Institution
Stanford UniversityResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnosticsResearch Subcategory
ImmunitySpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
For using their combined expertise in virology and in multisubunit protein production to engineer virus-like particles (VLPs), which will allow for rapid testing of the neutralization capacity of recovered patient sera (in collaboration with the Blish lab) or designed antibodies targeting the S protein (in collaboration with the Wells lab).